Trials / Completed
CompletedNCT03798366
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis
A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered GLPG1690 for 24 Weeks in Subjects With Systemic Sclerosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Galapagos NV · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of the study is to see if GLPG1690 helps (together with the standard of care treatment) in the treatment of the skin and other areas affected by systemic sclerosis. Another aim is to find out how safe/well tolerated GLPG1690 will be and whether there are any side effects. The study will also look at other things, including whether the study drug affects disease progression and also if it changes any aspect of the quality of life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLPG1690 | Film-coated tablets of GLPG1690 for oral use. |
| DRUG | Placebo | Film-coated tablets of GLPG1690 matching placebo for oral use. |
Timeline
- Start date
- 2019-01-14
- Primary completion
- 2020-05-21
- Completion
- 2020-06-22
- First posted
- 2019-01-09
- Last updated
- 2021-05-04
- Results posted
- 2021-05-04
Locations
18 sites across 6 countries: United States, Belgium, Germany, Italy, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03798366. Inclusion in this directory is not an endorsement.